Vacuum-assisted breast biopsy on digital stereotaxic table of nonpalpable lesions non-recognisable by ultrasonography

Abstract

The aim of this study was to evaluate accuracy of 11 G vacuum-assisted percutaneous biopsy (VAPB) carried out on digital stereotaxic table, on breast non-palpable lesions (NPLs), non-visible by US. Prospective study on 132 consecutive NPLs (126 patients) not reliably found by US; 82% showed microcalcifications. Surgical confirmation was obtained in all malignant cases and when VAPB reported atypical lesion (ductal or lobular), radial scar or atypical papillary lesion. All patients with benign results were included in a mammographic follow-up programme. Two cases could not be dealt with due to technical difficulties. One to 26 cylinders were obtained from the remaining 130 NPLs. Sixty-four lesions were surgically confirmed. Forty-six of the 47 malignancies were correctly diagnosed. In one case of a malignant tumour, an atypical lesion was classified with VAPB. All cases of histologically verified lobular carcinoma in situ, atypical ductal or lobular hyperplasia, radial scar or atypical papillary lesion were correctly diagnosed preoperatively. The remaining lesions were benign in VAPB, and after 1 year of follow-up, no false negative has been found. Based on this short-term follow-up, absolute sensitivity was 97.9%, absolute specificity 84.3% and accuracy was 99.2%. For predicting invasion, accuracy was 89.1%. Vacuum-assisted percutaneous biopsy is a very accurate technique for NPLs which are not detectable by US. It can replace approximately 90% of DSB with no important complications, avoiding scars and providing a higher level of comfort.

Mammotome® and EnCor®: comparison of two systems for stereotactic vacuum-assisted core biopsy in the characterisation of suspicious mammographic microcalcifications alone

“…A failure occurred only in one case with the EnCor ® probe. However, this finding cannot be attributed to the system used, since failure rates between 0 and 5 % with Mammotome ® system in previous studies have been described [21][22][23].…”

Stereotactic and ultrasound-guided breast biopsy

“…Radiologists must not only decide which of these technologies to use, but also which size needle or probe is the most appropriate in each case. Cost, clinical context, and likely diagnosis should influence the decision process [1,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,48,49,50,51,52]. a suitable examination table (Fischer Imag-ing Mammotest, Denver, Colo.).…”

“…Three imaging modalities are currently used to perform percutaneous biopsy: ultrasound; stereotactic (X-ray) imaging; and MR imaging. Acquisition of tissue is usually accomplished by fine-needle aspiration (FNA) or by removal of larger volumes of tissue through various cutting needles (automated large-core needles) and directional vacuum-assisted biopsy probes [1,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,48,49,50,51,52].…”

The causes of failure in removing calcium in ‘microcalcification only’ lesions at 11-gauge stereotactic vacuum-assisted biopsy

“…The rate of failure to retrieve breast microcalcifications after an 11-gauge VAB prone to stereotactic biopsy is reported to be between 0% and 5% (5,18,19,(21)(22)(23)(24)(25)(26). This rate was lower than the rate of failure to retrieve breast microcalcifications with 14-gauge core biopsy, which was 0%-16% (5,19,21,23,27) (Table 4).…”